EuroPharma Today

European HTA Round-Up: NICE Focuses On Cost Effectiveness, IQWiG On Clinical Benefit, But Convergence May Come

Josh — Mon, 06 Feb 2012 11:20:36 PST

It is becoming increasingly clear that NICE and IQWiG have very different concerns on the reimbursement front, but it is only a matter of time before IQWiG gets its teeth into cost-benefit analyses.

For Novartis, 2012 Is Set To Be A Bumpy Ride

Josh — Mon, 30 Jan 2012 08:52:43 PST

With the loss of exclusivity for its blockbuster heart drug, Diovan, coming in September, management focused on the company’s long-term prospects during a fourth quarter financial update.

Austerity Holds Back VC Investing in European Biotech Companies in 2011

Josh — Tue, 24 Jan 2012 09:37:25 PST

Funding for private biotech companies in Europe declines 17% during 2011, while funding for public biotech companies falls 50%, although 2012 starts strongly.

U.K. To Leverage NHS Data As Part Of Broader Stimulus Package, But Details Still Sketchy

Josh — Thu, 05 Jan 2012 09:04:12 PST

Industry welcomed the initiatives, which included making National Health Service clinical data more widely available and strengthening NICE's role.

Grunenthal CEO Claims German Reimbursement Hurdle Is Fair, As Pain Drug Palexia Rolls Out Across Europe

Josh — Tue, 03 Jan 2012 11:01:24 PST

German reimbursement authority’s strong emphasis on drugs’ added benefit is logical, opines Grunenthal CEO Harald Stock. And all health care systems will eventually move the same way.

AZ’s Brillinta Is First Drug To Clear AMNOG Assessment, While Merck’s Victrelis Limps Forward

Josh — Mon, 19 Dec 2011 09:31:17 PST

Lack of consistent approach in IQWiG/G-BA AMNOG-based decisions leaves industry confused about new reimbursement route.

Euro Crisis Hits Investor Risk Appetite, But Opportunities Remain

Josh — Mon, 12 Dec 2011 09:26:17 PST

There are good-value opportunities in Europe for VCs with money to invest, but those seeking new funds face an unprecedentedly tough challenge that’s compounded by euro uncertainty.

The End of The Euro: What Might It Mean For Pharma?

Josh — Mon, 05 Dec 2011 10:24:47 PST

Companies struggle on how even to begin assessing impact of a possible Euro break-up.

The End of The Euro: What Might It Mean For Pharma?

Josh — Mon, 05 Dec 2011 10:22:05 PST

Companies struggle on how even to begin assessing impact of a possible Euro break-up.

French Pharma Industry Pays The Price For Country’s Financial Woes

Josh — Mon, 21 Nov 2011 09:33:22 PST

In an effort to shore up its credit rating, the French government has turned the financial screw on pharmaceutical manufacturers.